Upsides

When other topical therapies are ineffective or unsafe, it may be used to treat moderate-to-severe eczema (atopic dermatitis) in adults and children aged 6 months and older. It is safe to use with or without topical corticosteroids.

As a maintenance add-on therapy for adults and children 6 years of age and older, it may also be used for moderate-to-severe eosinophilic asthma (a condition marked by elevated levels of the white blood cells known as eosinophils). A flare-up of asthma is NOT treated with dupixent.

Can be used in addition to other treatments for chronic rhinosinusitis with nasal polyps in adults and eosinophilic esophagitis in adults and children aged 12 and up who weigh at least 40 kg.

Is the first (and currently only) approved treatment for Prurigo Nodularis, a chronic, debilitating skin disease that has a significant impact on a person's quality of life.

Steroid-free.

Subcutaneous injection is used to administer the medication (under the skin).

Pre-filled syringes and pre-filled pens are available. The pre-filled pen is only for patients over the age of 12. The pre-filled pen contains a dose of 300 mg. The pre-filled syringe is available in 200 mg or 300 mg doses.

Dupixent patients can be taught how to self-administer the injection.

Usually administered every two weeks (every other week). Dupixent should be given every four weeks to children weighing 15kg to less than 30kg.

Because it does not suppress the immune system, it is not classified as an immunosuppressant.

Although it is not a cure for eczema, it does reduce symptoms (such as itching, rash, and flare frequency) in two-thirds to three-fourths of those who take it. However, there appears to be a subset of people who only respond partially to Dupixent (partial responders), or who respond initially and then have their symptoms return (non-durable responders).